DBV Technologies Announces Filing of 2020 Annual Report on Form 10-K and 2020 Universal Registration Document
March 17 2021 - 6:30PM
Montrouge, France, March 17, 2021
DBV Technologies Announces Filing of
2020 Annual Report on Form 10-K and 2020 Universal Registration
Document
The Company also announces that it will
enter the SBF 120 Index on Euronext
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT) today announced the
filing of its first Annual Report on Form 10-K for the year ended
December 31, 2020, with the U.S. Securities and Exchange Commission
(SEC) and the filing of its 2020 Universal Registration Document
(URD) for the year ended December 31, 2020 with the French market
authority “Autorité des Marchés Financiers” (AMF) under the number
D.21-0141.
These documents can be accessed on the Investors
& Media section of the Company's website at
www.dbv-technologies.com. In addition, the Universal Registration
Document is available on the AMF’s website at www.amf-france.org
and the Form 10-K is available on the SEC’s website at
www.sec.gov.
Printed copies of both documents are available,
free of charge, at the Company’s headquarters and registered office
located at 177-181 avenue Pierre Brossolette 92120 Montrouge,
France.
DBV also announced that, following the March
2021 review of the Euronext Paris Stock Exchange Indices, the
“Conseil Scientifique des Indices”, Euronext’s steering committee,
has admitted DBV to the SBF 120 Index.
This decision will take effect from March 22,
2021. The SBF 120 Index (Société des Bourses Françaises 120 Index)
groups the Euronext’s 120 largest companies by market
capitalization and trading volumes.
About DBV TechnologiesDBV
Technologies is developing Viaskin™, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPIT™, DBV’s method of delivering biologically active compounds to
the immune system through intact skin. With this new class of
non-invasive product candidates, the Company is dedicated to safely
transforming the care of food allergic patients. DBV’s food
allergies programs include ongoing clinical trials of Viaskin
Peanut. DBV Technologies has global headquarters in Montrouge,
France and offices in Bagneux, France, and North American
operations in Summit, NJ and New York, NY. The Company’s ordinary
shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), and the Company’s ADSs (each representing
one-half of one ordinary share) are traded on the Nasdaq Global
Select Market (Ticker: DBVT).
DBV Investor Relations Contact
Anne PollakDBV Technologies+1
857-529-2363anne.pollak@dbv-technologies.com
Media ContactAngela MarcucciDBV
Technologies+1 646-842-2393angela.marcucci@dbv-technologies.com
DBV Technologies (EU:DBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
DBV Technologies (EU:DBV)
Historical Stock Chart
From Apr 2023 to Apr 2024